Small molecule · developed by Lantheus Medcl
Gadofosveset trisodium is a gadolinium-based contrast agent that binds reversibly to serum albumin, which prolongs its intravascular residence time and increases blood signal on magnetic resonance angiography. It is used to visualize blood vessels and has been studied in pulmonary embolism.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 9, 2017). Read the full label for the exact wording, limitations and safety information.
Pulmonary Embolism
Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →